MetLife Investment Management’s Relmada Therapeutics RLMD Stock Holding History

MetLife Investment Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,091	Closed	-$522K	–	2841
2022 Q3	$522K	Hold	14,091	–	–	﹤0.01%	1601
2022 Q2	$268K	Hold	14,091	–	–	﹤0.01%	2104
2022 Q1	$380K	Buy	14,091 +7,337	+109%	+$152K	﹤0.01%	1951
2021 Q4	$152K	Hold	6,754	–	–	﹤0.01%	2222
2021 Q3	$177K	Hold	6,754	–	–	﹤0.01%	2172
2021 Q2	$216K	Hold	6,754	–	–	﹤0.01%	2119
2021 Q1	$238K	Hold	6,754	–	–	﹤0.01%	1962
2020 Q4	$217K	Hold	6,754	–	–	﹤0.01%	1943
2020 Q3	$254K	Hold	6,754	–	–	﹤0.01%	1714
2020 Q2	$302K	Buy	+6,754	New	+$286K	﹤0.01%	1650

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's RLMD Position: Q4 2022 in Review

MetLife Investment Management sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 14,091 shares — an estimated $522K sold.

MetLife Investment Management first reported a position in RLMD in Q2 2020 and held it in 10 quarters. The position peaked at $522K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

MetLife Investment Management reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
MetLife Investment Management sold 14,091 Relmada Therapeutics shares in Q4 2022, an estimated $522K.
MetLife Investment Management first reported a position in Relmada Therapeutics in Q2 2020 and held it in 10 quarters.
MetLife Investment Management's Relmada Therapeutics position peaked at $522K in Q3 2022.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.